ANDA 62900, held by Watson Labs. Clindamycin Phosphate.
As of Nov 15, 2026, ANDA 62900 (Clindamycin Phosphate), held by Watson Labs, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Clindamycin PhosphateEQ 150MG BASE/ML ยท injectable;injection | Clindamycin Phosphate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
